294
Participants
Start Date
September 30, 2013
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
lixisenatide AVE0010
Pharmaceutical form:solution Route of administration: Subcutaneous injection
biguanide
Pharmaceutical form:tablet Route of administration: oral
TZD
Pharmaceutical form:tablet Route of administration: oral
alpha-GI
Pharmaceutical form:tablet Route of administration: oral
glinide
Pharmaceutical form:tablet Route of administration: oral
Investigational Site Number 392335, Adachi-Ku
Investigational Site Number 392325, Chiba
Investigational Site Number 392328, Chiyoda-Ku
Investigational Site Number 392310, Chuoh-Ku
Investigational Site Number 392326, Chūōku
Investigational Site Number 392327, Chūōku
Investigational Site Number 392336, Kagoshima
Investigational Site Number 392314, Kamakura-Shi
Investigational Site Number 392334, Kashiwara-Shi
Investigational Site Number 392304, Kawagoe-Shi
Investigational Site Number 392306, Kawaguchi-Shi
Investigational Site Number 392307, Kisarazu-Shi
Investigational Site Number 392301, Koriyama-Shi
Investigational Site Number 392312, Mitaka-Shi
Investigational Site Number 392302, Mito
Investigational Site Number 392324, Mito
Investigational Site Number 392331, Nagoya
Investigational Site Number 392332, Nagoya
Investigational Site Number 392329, Ohta-Ku
Investigational Site Number 392322, Okawa-Shi
Investigational Site Number 392333, Osaka
Investigational Site Number 392330, Sagamihara-Shi
Investigational Site Number 392320, Saijo-Shi
Investigational Site Number 392303, Sakado-Shi
Investigational Site Number 392311, Shinjuku-Ku
Investigational Site Number 392316, Shizuoka
Investigational Site Number 392319, Suita-Shi
Lead Sponsor
Sanofi
INDUSTRY